natgillin/translations-raw huggingface dataset:
In women with recent or ongoing thromboembolic disease or women with generally recognised risk factors for thromboembolic events, such as personal or family history, thrombophilia or severe obesity (body mass index >30 kg/m2), treatment with gonadotropins may further increase the risk for aggravation or occurrence of such events. 
Pri ženskah z nedavno ali trenutno prisotno trombembolično boleznijo ali pri ženskah s splošno znanim dejavnikom tveganja za trombembolične dogodke, na primer v anamnezi ali v družinski anamnezi, ter pri ženskah s trombofilijo ali hudo debelostjo (indeks telesne mase > 30 kg/m2) lahko zdravljenje z gonadotropini dodatno zviša tveganje za poslabšanje ali prisotnost takih dogodkov.
• Serious blood clotting complications (thromboembolic events) usually with severe OHSS are found very rarely. 
• Hudi zapleti strjevanja krvi (trombembolični dogodki) običajno s hudim OHSS, se pojavijo zelo redko.
Gently push the plunger until the air bubbles are gone. 
Nežno potiskajte bat, dokler zračni mehurčki ne izginejo.
Luveris is intended for subcutaneous use which means it is given by injection under the skin. 
Zdravilo Luveris je namenjeno za subkutano uporabo, kar pomeni, da se ga injicira pod kožo.
Luveris is recommended for the treatment of adult women who have been shown to produce very low levels of some of the hormones involved in the natural reproductive cycle. 
Zdravilo Luveris se priporoča za zdravljenje odraslih žensk, za katere se je izkazalo, da tvorijo zelo majhne količine nekaterih hormonov, ki predstavljajo del naravnega reproduktivnega ciklusa.
In distinction to uncomplicated ovarian enlargement, OHSS is a condition that can manifest itself with increasing degrees of severity. 
V nasprotju z nekompliciranim povečanjem jajčnikov je OHSS stanje, ki se lahko kaže s stopnjevanjem resnosti.
Treatment should recommence in the next cycle at a dose of FSH lower than that of the previous cycle. 
Ponovno zdravljenje v naslednjem ciklusu se mora začeti z nižjim odmerkom FSH-ja kot v predhodnem ciklusu.
If severe OHSS occurs, it is recommended that gonadotropin treatment be stopped if still ongoing and that the patient be hospitalised and appropriate therapy be started. 
Če se razvije huda oblika OHSS, priporočamo, da zdravljenje z gonadotropini, če to še traja, ustavite in da bolnico hospitalizirate ter začnete z ustrezno terapijo.
Alternatively, intrauterine insemination (IUI) may be performed. 
Alternativno se lahko izvede intrauterina osemenitev (IUI).
Treatment should be tailored to the individual patient's response as assessed by measuring follicle size by ultrasound and oestrogen response. 
Zdravljenje mora biti prilagojeno individualnemu odzivu bolnice, katerega ovrednotimo z merjenjem velikosti folikla z ultrazvokom in estrogenskega odziva.
• Dispose of all used items: Once you have finished your injection, immediately discard all needles and empty glass containers in the sharps container provided. 
• Odstranite vse uporabljene predmete: ko ste zaključili z vbrizgavanjem, takoj odstranite vse igle in prazne steklene vsebnike v zaščitno posodo, ki je priložena.
Your ovaries may have over-reacted to the treatment and formed large sacs of fluid or cysts (see also in section 2 under “Ovarian HyperStimulation Syndrome”). 
Vaši jajčniki so se morda prekomerno odzvali na zdravljenje in razvile so se velike vrečke s tekočino ali ciste (glejte tudi poglavje 2 „Sindrom hiperstimulacije jajčnikov“).
Talk to your doctor before using Luveris if you or a member of your family have ever had blood clots in the leg or in the lung, or a heart attack or stroke. 
Težave s strjevanjem krvi (trombembolični dogodki) Pred uporabo zdravila Luveris se posvetujte z zdravnikom, če ste vi ali član vaše družine kdaj imeli krvne strdke v nogi ali pljučih ali če ste vi ali član vaše družine kdaj doživeli srčni napad ali kap.
Ovarian torsion has been reported after treatment with other gonadotropins. 
O zasuku jajčnika so poročali po zdravljenju z ostalimi gonadotropini.
This could cause chest pain, breathlessness, stroke or heart attack (see also in section 2 under “Blood clotting problems”). 
Ti povzročajo bolečine v prsnem košu, težko dihanje, kap ali srčni napad (glejte tudi poglavje 2 „Težave s strjevanjem krvi“).
If you are developing OHSS your doctor may not give you any hCG in this treatment cycle and you may be told not to have sex or to use a barrier contraceptive method for at least four days. 
Če se pri vas razvije OHSS, vam zdravnik v tem ciklusu zdravljenja morda ne bo dal hCG in vam bo naročil, da v obdobju najmanj štirih dni nimate spolnih odnosov ali da v tem času uporabljate mehanska kontracepcijska sredstva.
Other medicines and Luveris 
Druga zdravila in zdravilo Luveris
For the following cycle, your doctor will prescribe FSH at a lower dose than that of the previous cycle. 
Za naslednji ciklus vam bo zdravnik predpisal manjši odmerek FSH kot v predhodnem ciklusu.
Multiple pregnancy, especially high order, carry an increased risk of adverse maternal and perinatal outcomes. 
Večplodna nosečnost, zlasti visokega reda, predstavlja povečano tveganje za neželen izid nosečnosti za mater in otroka.
This side effect is very rare (may affect up to 1 in 10,000 people). 
Ti neželeni učinki so zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov).
Safety, efficacy, and pharmacokinetics of Luveris in patients with renal or hepatic impairment have not been established. 
Varnost, učinkovitost in farmakokinetika zdravila Luveris pri bolnikih z ledvično ali jetrno okvaro niso bile dokazane.
Important information about some of the ingredients of Luveris Luveris contains less than 1 mmol sodium (23 mg) per dose. 
Pomembne informacije o nekaterih sestavinah zdravila Luveris Zdravilo Luveris vsebuje manj kot 1 mmol (23 mg) natrija na odmerek.
Luveris is contraindicated in patients with: 
Zdravilo Luveris je kontraindicirano pri bolnicah:
• ovarian enlargement or ovarian cyst unrelated to polycystic ovarian disease and of unknown origin 
• s povečanjem jajčnikov ali cisto jajčnikov, ki ni povezana s policistično boleznijo ovarijev in je neznanega izvora
Following intravenous administration, lutropin alfa is rapidly distributed with an initial half-life of approximately one hour. 
Po intravenskem dajanju se lutropin alfa hitro porazdeli z začetnim razpolovnim časom približno 1 uro.
This becomes more likely if the medicine that is used for final follicular maturation (containing human Chorionic Gonadotropin, hCG) is administered (see in section 3 under “How much to use” for details). 
To postane bolj verjetno, če jemljete zdravilo, ki se uporablja za sprožitev končnega folikularnega zorenja (ki vsebuje humani horionski gonadotropin, hCG) (za podrobnosti glejte poglavje 3 „Koliko zdravila uporabiti“.
Safety and effectiveness of Luveris in elderly patients have not been established. 
Varnost in učinkovitost zdravila Luveris pri starejših bolnikih nista bili dokazani.
Directly below it is where the neck of the ampoule has been treated to make it easier to break. 
Direktno pod njo je vrat ampule, ki je obdelan tako, da ga je najlažje zlomiti.
Following subcutaneous administration, the terminal half-life is slightly prolonged. 
Po subkutanem dajanju je končni razpolovni čas rahlo podaljšan.
In patients with porphyria or a family history of porphyria Luveris may increase the risk of an acute attack. 
Pri bolnicah s porfirijo ali pri bolnicah, ki imajo porfirijo v družini, lahko zdravilo Luveris poveča tveganje za akutni napad.
If an excessive response is obtained, treatment should be stopped and hCG withheld (see section ‘Possible Side Effects'). 
Če pride do čezmernega odziva, je treba zdravljenje prekiniti in opustiti hCG (glejte poglavje „Možni neželeni učinki“).
One ampoule of solvent contains: 1 ml water for injection. 
Ena ampula z vehiklom vsebuje: 1 ml vode za injekcije.
If you are not sure, talk to your doctor or pharmacist before using this medicine. 
Če niste prepričani, se pred uporabo zdravila pogovorite z zdravnikom ali farmacevtom.
One vial of powder for injection contains 75 IU (International Units). 
Ena viala s praškom za injiciranje vsebuje 75 i.e. (internacionalne enote).
Luveris is usually used every day for up to three weeks simultaneously with injections of FSH. 
Zdravilo Luveris je treba jemati vsak dan največ tri tedne skupaj z injekcijami FSH.
• The active substance is lutropin alfa. 
• Zdravilna učinkovina je lutropin alfa.
• gynaecological haemorrhages of unknown origin 
• z ginekološkimi krvavitvami neznanega izvora
If you get lower abdominal pain, gain any weight rapidly, feel sick or are vomiting or if you have difficulty in breathing, talk to your doctor straight away who might ask you to stop using this medicine (see in section 4 under “Serious side effects”). 
Če občutite bolečino v spodnjem delu trebuha, hitro pridobite na telesni masi, vam je slabo ali bruhate ali če je vaše dihanje oteženo, se takoj pogovorite z zdravnikom, ki vam bo morda naročil, da prenehate jemati to zdravilo (glejte poglavje 4 „ Resni neželeni učinki“).
Name and address of the manufacturer responsible for batch release Merck Serono S.p.A. 
Ime in naslov izdelovalca, odgovornega za sproščanje serij Merck Serono S.p.A.
• ovarian, uterine, or mammary carcinoma 
• z ovarijskim, materničnim karcinomom ali karcinomom dojke
Following subcutaneous administration of Luveris, lutropin alfa is eliminated from the body with a terminal half-life of about 10-12 hours. 
Po subkutanem dajanju zdravila Luveris se lutropin alfa izloči iz telesa s končnim razpolovnim časom približno 10-12 ur.
The powder is packaged in 3 ml neutral colourless glass (type I) vials. 
Prašek je pakiran v 3 ml viale iz nevtralnega brezbarvnega stekla (tip I).
This leaflet was last revised in . 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL}
Clinical evaluation may reveal signs such as hypovolaemia, haemoconcentration, electrolyte imbalances, ascites, pleural effusions, or acute pulmonary distress. 
Klinični pregled lahko pokaže znake, kot so hipovolemija, hemokoncentracija, elektrolitsko neravnovesje, ascites, plevralni izliv ali akutna pulmonalna stiska.
If you administer Luveris to yourself, please carefully read the following instructions: • Wash your hands. 
Če si sami dajete zdravilo Luveris, vas prosimo, da natančno preberete naslednja navodila:
Independent risk factors for developing OHSS include young age, lean body mass, polycystic ovarian syndrome, higher doses of exogenous gonadotropins, high absolute or rapidly rising serum estradiol levels and previous episodes of OHSS, large number of developing ovarian follicles and large number of oocytes retrieved in ART cycles. 
Samostojni dejavniki tveganja za razvoj OHSS vključujejo mlada leta, mršavo telesno maso, sindrom policističnih jajčnikov, večje odmerke eksogenih gonadotropinov, visoke absolutne ali hitro rastoče ravni serumskega estradiola in predhodno pojavljanje OHSS, veliko število razvijajočih se ovarijskih foliklov in veliko število oocitov v ciklusih ART.
What Luveris is and what it is used for 
Kaj je zdravilo Luveris in za kaj ga uporabljamo
Luveris should not be administered as a mixture with other medicinal products, in the same injection, except follitropin alfa for which studies have shown that co-administration does not significantly alter the activity, stability, pharmacokinetic nor pharmacodynamic properties of the active substances. 
Zdravila Luveris ne smemo dajati kot mešanico z drugimi zdravili v isti injekcijski brizgi, razen s folitropinom alfa, za katerega so študije pokazale, da njegovo sočasno dajanje ne spremeni pomembno učinka, stabilnosti, farmakokinetičnih ali farmakodinamičnih lastnosti zdravilnih učinkovin.
Carefully place the open ampoule upright on the worksurface. 
Odprto ampulo previdno položite v pokončnem položaju na delovno površino.
Lutropin alfa shows linear pharmacokinetics, as assessed by area under curve (AUC) which is directly proportional to the dose administered. 
Lutropin alfa izkazuje linearno farmakokinetiko, kot so ocenili s površino pod krivuljo (AUC), ki je direktno sorazmerna danemu odmerku.
Before starting treatment, the couple's infertility should be assessed as appropriate and putative contraindications for pregnancy evaluated. 
Pred začetkom zdravljenja je treba primerno oceniti neplodnost para in ovrednotiti domnevne kontraindikacije za nosečnost.
• The solvent is water for injection. 
• Vehikel je voda za injekcije.
Vascular disorders Very rare: Thromboembolism, usually associated with severe OHSS 
Žilne bolezni Zelo redki: trombembolija, običajno povezana s hudim OHSS
Inspect for particles as before, and do not use if the solution is not clear. 
Enako kot prej, raztopino preglejte na prisotnost delcev in je ne uporabite, če ni bistra.
Immune system disorders Very rare: Mild to severe hypersensitivity reactions including anaphylactic reactions and shock. 
Bolezni imunskega sistema Zelo redki: blaga do huda preobčutljivostna reakcija, vključno z anafilaktičnimi reakcijami in šokom
Nervous system disorders Common: Headache 
Bolezni živčevja Pogosti: glavobol
However, drug-related teratogenesis was not observed in either animal model. 
Vendar pa pri nobenem od živalskih modelov niso opazili z zdravilom povezane teratogenosti.
• fibroid tumours of the uterus incompatible with pregnancy 
• fibroidni tumorji maternice, nezdružljivi z nosečnostjo
No signs of toxicity due to the development of antibodies to lutropin alfa were observed. 
Toksičnosti zaradi razvoja protiteles za lutropin alfa niso opazili.
Luteal phase support may be considered since lack of substances with luteotrophic activity (LH/hCG) after ovulation may lead to premature failure of the corpus luteum. 
Pretehta naj se potrebnost podpore lutealne faze, ker pomanjkanje snovi z luteotropno aktivnostjo (LH/hCG) po ovulaciji lahko privede do prezgodnje odpovedi rumenega telesca.
Date of latest renewal: 30 
Datum zadnjega podaljšanja: 30. november 2005.
The majority of multiple conceptions are twins. 
V večini primerov večplodne nosečnosti gre za dvojčke.
• Immediately inject the solution: Your doctor or nurse will have already advised you where to inject (e.g. tummy, front of thigh). 
• Takoj vbrizgajte raztopino: Vaš zdravnik ali sestra sta vas že poučila, kje dati injekcijo (npr. v trebuh, sprednjo stran stegna).
What Luveris is and what it is used for What you need to know before you use Luveris How to use Luveris 
Kaj je zdravilo Luveris in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Luveris Kako uporabljati zdravilo Luveris Možni neželeni učinki
This side effect is common (may affect up to 1 in 10 people). 
Ta neželeni učinek je pogost (pojavijo se lahko pri največ 1 od 10 bolnikov).
The vials are sealed with bromobutyl stoppers protected by aluminium seal rings and flip-off caps. 
Viale so zaprte z bromobutilnimi zamaški, ki so zaščiteni z aluminijastimi zapornimi obročki in zaporkami, ki se odtrgajo na poteg.
When undergoing assisted reproductive technology or stimulation of your ovaries to produce eggs, you are more likely to have a miscarriage than the average woman. 
Če poskušate zanositi z biomedicinsko pomočjo ali stimulacijo jajčnikov za proizvajanje jajčec, je verjetnost, da boste imeli spontani splav, večja kot pri povprečni ženski.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
IME ZDRAVILA IN POT(I ) UPORABE
It is recommended not to use Luveris if you have any condition that usually makes a normal pregnancy impossible, such as ovaries that do not work because of a condition called primary ovarian failure, or malformations of sexual organs. 
Jemanje zdravila Luveris ni priporočljivo, če imate stanje, ki običajno onemogoča normalno zanositev, kot je nedelovanje jajčnikov zaradi primarne odpovedi jajčnika ali malformacije spolnih organov.
In clinical trials, patients were defined by an endogenous serum LH level < 1.2 IU/l as measured in a central laboratory. 
V kliničnih preskušanjih so bile bolnice opredeljene na podlagi serumske ravni endogenega LH < 1,2 i.e./l, izmerjene v centralnem laboratoriju.
• Local reactions at the injection site, such as pain, itching, bruising, swelling or irritation. 
• lokalne reakcije na mestu injiciranja, kot so bolečina, srbenje, modrica, oteklina ali draženje.
The lutropin alfa pharmacokinetics following single and repeated administration of Luveris are comparable and the accumulation ratio of lutropin alfa is minimal. 
Farmakokinetika lutropina alfa po enkratnem in večkratnem dajanju zdravila Luveris je primerljiva, stopnja akumulacije lutropina alfa pa je minimalna.
The reconstituted solution should not be administered if it contains particles or is not clear. 
Rekonstituirane raztopine ne smemo uporabiti, če vsebuje delce ali ni bistra.
Luveris is intended for subcutaneous use. 
Zdravilo Luveris je namenjeno subkutani uporabi.
Luveris has no or negligible influence on the ability to drive and use machines. 
Zdravilo Luveris nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
The solvent is packaged either in 2 or 3 ml neutral colourless glass (type I) vials with a Teflon-coated rubber stopper or in 2 ml neutral colourless glass (type I) ampoules. 
Vehikel je pakiran bodisi v 2 ml ali 3 ml viale iz nevtralnega brezbarvnega stekla (tip I), z gumijastimi zamaški, prevlečenimi s teflonom ali v 2 ml ampule iz nevtralnega brezbarvnega stekla (tip I).
This increases your risk of developing Ovarian HyperStimulation Syndrome or OHSS. 
To poveča tveganje za razvoj sindroma hiperstimulacije jajčnikov ali OHSS.
Adherence to recommended Luveris and FSH dosage and regimen of administration can minimise the risk of ovarian hyperstimulation. 
Upoštevanje priporočenih odmerkov zdravila Luveris in FHS-ja ter režim dajanja lahko zmanjšata tveganje za hiperstimulacijo jajčnikov.
Luveris is a medicine containing lutropin alfa, a recombinant Luteinising Hormone (LH) which is essentially similar to the hormone found naturally in humans, but is made by means of biotechnology. 
Luveris je zdravilo, ki vsebuje lutropin alfa, rekombinantni luteinizirajoči hormon (LH), ki je zelo podoben naravnemu hormonu pri ljudeh, vendar je izdelan s pomočjo biotehnologije.
Data on a limited number of exposed pregnancies indicate no adverse reactions of gonadotropins on pregnancy, embryonal or foetal development, parturition or postnatal development following controlled ovarian stimulation. 
Podatki, zbrani pri omejenem številu nosečnic, ki so bile izpostavljene zdravilu, ne kažejo na možnost škodljivih vplivov gonadotropinov na nosečnost, razvoj zarodka ali plodu, porod ali postnatalni razvoj po nadzorovani stimulaciji jajčnikov.
Luteinising Hormone (LH) binds on the ovarian theca (and granulosa) cells and testicular Leydig cells, to a receptor shared with human chorionic gonadotropin hormone (hCG). 
Luteinizirajoči hormon (LH) se veže na ovarijske teka (in granuloza) celice in na Leydigove celice testisov, na receptor, ki je skupen humanemu horionskemu gonadotropinskemu hormonu (hCG).
It comprises marked ovarian enlargement, high serum sex steroids, and an increase in vascular permeability which can result in an accumulation of fluid in the peritoneal, pleural and, rarely, in the pericardial cavities. 
Vključuje izrazito povečanje jajčnikov, visoko serumsko koncentracijo spolnih steroidov ter povečanje žilne prepustnosti, kar lahko povzroči kopičenje tekočine v peritonealnem, plevralnem in redko v perikardialnem prostoru.
In clinical trials these patients were defined by an endogenous serum LH level <1.2 IU/l. 
V kliničnih preskušanjih so te bolnice opredelili glede na serumsko raven endogenega LH < 1,2 i.e./l.
It is followed by treatment with a single dose of human Chorionic Gonadotropin (hCG), which leads to the release of an egg from the follicle (ovulation). 
Temu sledi zdravljenje z enim samim odmerkom humanega horionskega gonadotropina (hCG), ki privede do sprostitve jajčeca iz folikla (ovulacije).
Torsion of the ovary and bleeding into the abdomen have not been reported with Luveris, however, there have been rare cases reported following treatment with human menopausal gonadotropin (hMG), a urine-derived medication also containing LH. 
Pri zdravljenju z zdravilom Luveris ne poročajo o torziji jajčnika in krvavitvah v trebuh, obstajajo pa poročila o redkih primerih le-tega po zdravljenju s humanim menopavznim gonadotropinom (hMG-jem), ki je zdravilo urinskega izvora in vsebuje tudi LH.
In case you are not ovulating, and if the recommended dose and schedule of administration are adhered to, the occurrence of OHSS is less likely. 
Če nimate ovulacije in če upoštevate priporočeni odmerek ter urnik dajanja, je pojav OHSS redek.
This could be due to parental factors (e.g. maternal age, genetics), ART procedures and multiple pregnancies. 
Vzrok so lahko dejavniki pri starših (npr. starost matere, genetika), postopki ART in večplodna nosečnost.
In patients undergoing induction of ovulation, the incidence of multiple pregnancy and births is increased compared with natural conception. 
Pri bolnicah v postopku indukcije ovulacije je pogostnost večplodne nosečnosti in rojstev povečana v primerjavi z naravno zanositvijo.
There is no relevant indication for the use of Luveris in the elderly population. 
Ni relevantnih podatkov o uporabi zdravila Luveris pri starejši populaciji.
After dissolving the Luveris powder, draw the solution back into the syringe and re-inject it into the container with the follitropin alfa powder. 
Ko se prašek zdravila Luveris raztopi, potegnite raztopino nazaj v brizgo in jo ponovno injicirajte v vsebnik s praškom folitropina alfa.
75 IU 
75 i.e.
In order to avoid the injection of large volumes, one vial of Luveris can be reconstituted together with one or two ampoule(s)/vial(s) of follitropin alfa, 37.5 IU, 75 IU or 150 IU, in 1 ml of solvent. 
V izogib injiciranju velikega volumna, lahko eno vialo zdravila Luveris rekonstituiramo skupaj z vsebino ene ali dveh ampul/vial s folitropinom alfa 37,5 i.e., 75 i.e. ali 150 i.e. v 1 ml vehikla.
If an FSH dose increase is deemed appropriate, dose adaptation should preferably be after 7-14 day intervals and preferably by 37.5 IU-75 IU increments. 
Če je potrebno povečanje odmerka FSH-ja, moramo prilagoditev odmerka izvesti po možnosti v 7-14 dnevnih intervalih s povečanji po 37,5 i.e. do 75 i.e.
A recommended regimen commences at 75 IU of lutropin alfa (ie. one vial of Luveris) daily with 75-150 IU FSH. 
Priporočeni režim se začne s 75 i.e. lutropina alfa (tj. Ena viala zdravila Luveris) na dan in s 75-150 i.e. FSH-ja.
Very rarely, severe OHSS may be complicated by ovarian torsion or thromboembolic events, such as pulmonary embolism, ischaemic stroke or myocardial infarction. 
Zelo redko se lahko huda stopnja OHSS še dodatno zaplete s torzijo jajčnika ali trombemboličnimi dogodki, kot so pulmonalni embolizem, ishemična kap ali miokardni infarkt.
In addition, patients should be evaluated for hypothyroidism, adrenocortical deficiency and hyperprolactinemia and appropriate specific treatment given. 
Poleg tega je pred začetkom zdravljenja bolnice treba pregledati še za hipotiroidizem, adrenokortikalno insuficienco in hiperprolaktinemijo ter jih ustrezno zdraviti.
Once the powder has dissolved, draw the solution back into the syringe. 
Ko se prašek raztopi, potegnite raztopino nazaj v brizgo.
The powder should be reconstituted immediately prior to use with the solvent provided. 
Prašek je treba rekonstituirati tik pred uporabo s priloženim vehiklom.
The effects of an overdose of Luveris are unknown, nevertheless there is a possibility that Ovarian Hyper-Stimulation Syndrome may occur, which is further described in ‘Possible side effects'. 
Če ste uporabili večji odmerek zdravila Luveris, kot bi smeli Učinki prevelikega odmerka zdravila Luveris niso poznani, vseeno pa je možen pojav sindroma ovarijske hiperstimulacije, kar je podrobno opisano v „Možni neželeni učinki“.